Want to see HK:2617 full AI Analyst Report?
TransThera Sciences (Nanjing). Inc. (2617) AI Stock Analysis
TransThera Sciences (Nanjing). Inc.
(HKEX:2617)
Low financial performance due to lack of revenue and sustained losses weighs heavily on the score, partially mitigated by balance sheet stability; mixed technical signals and unattractive valuation metrics contribute to the subdued overall rating.
TransThera Sciences (Nanjing). Inc. (2617) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 3.33B
- Dividend Yield
- ―
- Average Volume (3M)
- 7.03M
- Price to Earnings (P/E)
- -6.9
- Beta (1Y)
- 2.97
- Revenue Growth
- ―
- EPS Growth
- -13.19%
- Country
- Hong Kong
- Employees
- 132
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
TransThera Sciences (Nanjing). Inc. Business Overview & Revenue Model
Company Description
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a...
TransThera Sciences (Nanjing). Inc. Financial Statement Overview
Summary
Persistent net losses and zero revenue in this pre-revenue biotech firm are offset by a solid balance sheet with minimal debt and improving cash burn rates.
Income Statement
25NegativeBalance Sheet
70PositiveCash Flow
50Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.97M | 0 | 0 | 1.18M | 124.00K | 61.76M |
| Gross Profit | 30.68M | 0 | 0 | 1.18M | 124.00K | 0 |
| EBITDA | -267.59M | -290.82M | -267.97M | -413.42M | 8.55M | -39.27M |
| Net Income | -268.29M | -295.96M | -274.61M | -344.12M | -250.04M | -80.72M |
Balance Sheet | ||||||
| Total Assets | 987.24M | 545.91M | 629.60M | 887.09M | 1.35B | 344.94M |
| Cash, Cash Equivalents and Short-Term Investments | 925.22M | 489.14M | 572.53M | 838.17M | 1.11B | 279.34M |
| Total Debt | 5.61M | 1.65M | 4.37M | 4.81M | 3.04M | 490.74M |
| Total Liabilities | 109.26M | 129.53M | 104.57M | 103.91M | 111.04M | 578.87M |
| Stockholders Equity | 877.99M | 416.38M | 525.03M | 783.18M | 1.24B | -233.94M |
Cash Flow | ||||||
| Free Cash Flow | -144.55M | -253.68M | -271.95M | -331.12M | -244.00M | -76.61M |
| Operating Cash Flow | -144.47M | -253.51M | -271.18M | -319.33M | -241.94M | -66.68M |
| Investing Cash Flow | 108.03M | -68.00M | 348.42M | -186.94M | 26.98M | -195.84M |
| Financing Cash Flow | 1.55M | 169.00M | -4.87M | 15.76M | 240.45M | 311.48M |
TransThera Sciences (Nanjing). Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2617, the sentiment is Negative. The current price of 7.90 is below the 20-day moving average (MA) of 9.38, below the 50-day MA of 9.80, and below the 200-day MA of 39.38, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 34.35 is Neutral, neither overbought nor oversold. The STOCH value of 18.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2617.
TransThera Sciences (Nanjing). Inc. Peers Comparison
Overall Rating
HK:154871Outperform
HK:999566Neutral
HK:269664.6Neutral
HK:968846Neutral- HK:261744Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1548 | 71Outperform | HKD 79.58B | -14.95 | -16.23% | ― | 53.48% | -120.02% |
| HK:9995 | 66Neutral | HKD 51.82B | 7.89 | 105.60% | ― | 292.84% | ― |
| HK:2696 | 65Neutral | HKD 26.75B | 26.13 | 20.41% | ― | 32.63% | 8.74% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:9688 | 46Neutral | HKD 21.69B | -12.70 | -27.40% | ― | 5.38% | 16.86% |
| HK:2617 | 44Neutral | HKD 2.63B | -6.91 | -40.84% | ― | ― | -13.19% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2617 | TransThera Sciences (Nanjing). Inc. | 8.40 | -180.90 | -95.56% | |
| HK:1548 | Genscript Biotech Corporation | 35.02 | 17.98 | 105.52% | |
| HK:9688 | Zai Lab Ltd | 17.37 | -3.65 | -17.36% | |
| HK:9995 | RemeGen Co. Ltd. Class H | 64.85 | -28.00 | -30.16% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
TransThera Sciences (Nanjing). Inc. Corporate Events
TransThera Wins HKEX Nod for H-Share Full Circulation Conversion
TransThera Sciences (Nanjing), Inc. has received approval from the Hong Kong Stock Exchange to list 44,971,128 converted H shares, which will be transformed from the same number of previously unlisted shares. These converted shares, held by 10 partic...
TransThera Sciences Advances Full Circulation Plan for H Shares After CSRC Filing
TransThera Sciences (Nanjing), Inc., a PRC-based biopharmaceutical company listed on the Hong Kong Stock Exchange, is pursuing capital market optimization by converting a portion of its domestic shares into H shares to improve liquidity. The company&...
TransThera launches national rollout of first-in-China cholangiocarcinoma drug Yochanra
TransThera Sciences (Nanjing), Inc. has begun nationwide commercialisation of its core oncology drug Yochanra (tinengotinib tablets) in China after securing conditional marketing approval for adults with unresectable advanced or metastatic cholangioc...
TransThera’s Tinengotinib Secures CSCO Guideline Placement for Advanced Biliary Tract Cancers
TransThera Sciences has announced that its self-developed multi-target kinase inhibitor YOCHANRA (tinengotinib) has been included as a Class II, Class 2A recommendation in the 2026 Chinese Society of Clinical Oncology guidelines for the diagnosis and...
TransThera Starts Phase II Trial of Tinengotinib Combo in Resistant Prostate Cancer
TransThera Sciences (Nanjing), Inc., a China-based biopharma company specializing in innovative oncology drugs, is developing tinengotinib, a multi-target kinase inhibitor aimed at solid tumors such as cholangiocarcinoma and prostate cancer. With exi...
TransThera Sciences Narrows Interim Loss as Revenue Emerges Amid Rising R&D Spend
TransThera Sciences (Nanjing), Inc. reported its unaudited interim results for the six months ended 30 June 2026, posting revenue of RMB35.46 million versus no revenue a year earlier and a gross profit of the same amount as no cost of sales was recor...
TransThera Sciences Sets Board Meeting to Review Interim Results and Potential Dividend
TransThera Sciences (Nanjing), Inc. has scheduled a board meeting for 26 August 2026 to review and approve its unaudited consolidated interim results for the six months ended 30 June 2026. The board will also consider the declaration and payment of a...
TransThera Wins First China Approval for Yochanra in Advanced Cholangiocarcinoma
TransThera Sciences (Nanjing) has secured conditional marketing approval in China for its Class 1 new drug Yochanra, or tinengotinib tablets, to treat adult patients with unresectable advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 22, 2026